Speaker Profile

MS, MBA, General Partner, Norwest Venture Partners
Biography

With over 30 years of experience, Casper is a veteran of the medical device and life sciences industry, having led marketing and commercialization efforts for companies that span the healthcare space. He brings extensive operating knowledge to Norwest Venture Partners, where he focuses on mid-to-late-stage investments in consumer and digital health, healthcare IT, medical devices and diagnostics, technology-enabled healthcare services, and specialty pharmaceuticals. He currently serves on the boards of iRhythm Technologies (Nasdaq: IRTC), Crossover Health, Omada Health, and NextHealth Technologies. Casper was previously on the board of Basis (acquired by Intel) Intersect ENT (Nasdaq: XENT), and Telcare (acquired by BioTelemetry). Casper is also responsible for Norwest’s investment in Misfit Wearables (acquired by Fossil). Prior to Norwest, Casper was a Partner at U.S. Venture Partners (USVP) in Menlo Park, where he invested in therapeutic companies from clinical development through commercialization. At USVP, Casper served as a Board member for AtheroMed, Ilypsa (acquired by Amgen) and Valeritas. Over a six year period he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine, an orthopedic diagnostic company acquired by Kyphon in 2005.

Talk

Commercial Success to IPO: iRhythm CEO Interview
iRhythmn was the most successful diagnostic/digital health IPO of 2016. How does one build a >$600M commercial diagnostic company? Join us to hear about building operational excellence and the whirlwind path through clinical validation, FDA clearance, nationwide reimbursement, organization scaling, payments and contracting. Fireside chat with Kevin King, CEO.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!